Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

Mixed post-earnings tone: JNJ fell 5.7% on October 13 despite reported beats and a modest guidance lift, then gained 1.6% on October 14; the October 15 anchor was $253.28. Several post-print price targets were cut, although at least one was raised. The October 15 close remained below the pre-print level, so the initial negative reaction had not fully reversed. No reliable social, options-skew, short-interest or employee-sentiment measures were supplied; the zero placeholders above mean unavailable, not neutral readings. [Market reaction](https://www.kiplinger.com/investing/stocks/stocks-struggle-ahead-of-september-cpi-report-stock-market-today) [Benzinga revisions](https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62363208/these-analysts-cut-their-forecasts-on-johnson-and-johnson-after-q3-results) [October 15 close](https://www.marketscreener.com/quote/stock/JOHNSON-JOHNSON-4832/)

The October 14 close of $166.89 was 4.14% below the prior close, consistent with negative revenue-miss headlines despite the company raising parts of its full-year outlook. The -0.2 news score is a qualitative reading of the supplied headlines, not a measured feed. No verified post-print analyst revisions were available; the packet's $200.70 target lacks a count. Social, options, short-interest and employee-score zeros are unavailable-data placeholders, not measured neutral readings. The positive deterministic prior and strong primary earnings evidence justify monitoring for recovery, but not a bullish upgrade after the initial selloff. Price history: https://stockanalysis.com/stocks/stt/history/.

Merger coverage supplies a concrete company-specific narrative, but the scheduled earnings follow-up is not yet post-print. At 13:10 UTC on October 15, there is no confirmed fiscal fourth-quarter result, guidance change, analyst target revision, or post-release price move; zero-valued sentiment fields above denote unavailable measurements, not neutral observations. A pre-release Zacks item cited $0.84 EPS and $201.52 million revenue consensus, but those are expectations rather than reported results. [Zacks preview](https://finance.yahoo.com/markets/stocks/articles/wafd-wafd-earnings-expected-grow-130011856.html)

Company-reported results and wealth flows are positive, but early coverage describes shares slipping despite the beat ([Investing.com](https://www.investing.com/news/stock-market-news/why-is-morgan-stanley-stock-slipping-today-93CH-4948985)). Available third-party price reports conflict, so no precise post-release percentage move is asserted; the packet's $181.51 adjusted-close anchor is used for valuation. The T+1 analyst revision and target-change record is not yet established. Social, options, short-interest, and employee measures are unavailable rather than neutral.

Initial coverage frames Q3 as an EPS beat, but the beat was only $0.01 against the pre-release Zacks estimate and revenue missed that forecast. The $28.29 anchor is not a verified post-release trading reaction; no reliable T+1 price move, post-print analyst revision, or earnings-call transcript was available. The numerical sentiment fields other than headline buzz are unverified placeholders and should not be interpreted as measured signals. [#SEC-8K-2026-10-14] [Zacks results](https://www.zacks.com/stock/news/3007616/home-bancshares-homb-surpasses-q3-earnings-estimates)

The earnings-day reaction was mixed: [Investing.com](https://www.investing.com/news/stock-market-news/why-is-fastenal-stock-down-today-93CH-4948851) reported a 3.3% premarket decline, while [historical prices](https://stockanalysis.com/stocks/fast/history/) show a $52.00 close, up 1.11% from October 13. Strong company-reported growth and margin leverage contrast with the lower device-signings goal and spending concerns. Verified post-print analyst revisions are unavailable at this T+1 check; the packet has no sufficient social or options coverage, so the corresponding numeric fields are unavailable placeholders rather than observed sentiment.

FinancialContent - LeMaitre ( NASDAQ : LMAT ) Misses Q2 CY2026 Revenue Estimates , Stock Drops 11 . 6 %